Malignant ascites - Pipeline Insight, 2024

This “Malignant ascites - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant ascites pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malignant ascites Understanding

Malignant ascites: Overview

Ascites is the buildup of fluid in the space around the organs in the abdomen. When ascites is caused by cancer, it is called malignant ascites. The most common malignancies associated with the development of ascites include cancers of the colon/rectum, ovary, breast, lung, pancreas, liver, and lymphoma. Approximately 50% of patients with malignant ascites have peritoneal carcinomatosis with an additional 13% of patients having extensive liver metastases resulting in portal hypertension. Malignant ascites can develop through several mechanisms: blocked lymphatic channels as a result of malignancy, direct production of fluid into the peritoneal cavity by highly active cancers, and when “functional” cirrhosis develops in patients with extensive hepatic metastases resulting in portal hypertension. The development of malignant ascites carries a poor prognosis, with the median survival reported anywhere between 1 and 4 months.

Malignant ascites - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant ascites pipeline landscape is provided which includes the disease overview and Malignant ascites treatment guidelines. The assessment part of the report embraces, in depth Malignant ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Malignant ascites R&D. The therapies under development are focused on novel approaches to treat/improve Malignant ascites.

Malignant ascites Emerging Drugs Chapters

This segment of the Malignant ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant ascites Emerging Drugs

SCB-313: Clover Bio Pharmaceuticals With the Trimer-Tag™ technology platform, the company have developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. They are developing SCB-313 for the treatment of malignant ascites (MA), malignant pleural effusions (MPE), and peritoneal carcinomatosis (PC) to address global unmet medical need of intracavitary malignancies. The drug is currently in Phase I stage of clinical trial evaluation to treat malignantascites.

Malignant ascites: Therapeutic Assessment

This segment of the report provides insights about the different Malignant ascites drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Malignant ascites

There are approx. 5+ key companies which are developing the therapies for Malignant ascites. The companies which have their Malignant ascites drug candidates in the most advanced stage, i.e. phase I include, Clover Biopharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Malignant ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant ascites: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant ascites therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant ascites drugs.

Malignant ascites Report Insights

• Malignant ascites Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malignant ascites Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malignant ascites drugs?
• How many Malignant ascites drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant ascites?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant ascites therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant ascites and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Clover Biopharmaceuticals
• YZY Biopharma
• Sorrento Therapeutics, Inc.
• Simcere
• Pharma CyteBiotech
• Linton Pharm

Key Products

• SCB 313
• M 701
• CEA CAR-T cells
• Recombinant human endostatin
• Microencapsulated-P450-2B1-expressing-cells
• LP000

This product will be delivered within 1-3 business days.